Replies to post #203223 on Biotech Values

[mcbio]

Intriguing tidbit from RVNC 2Q16 PR/CC (#msg-124322727)

I just listened to this CC and a few comments/questions:

1. Thought it was interesting the comment about the acquisition of the patent portfolio having both "offensive" and "defensive" characteristics. Makes you wonder if RVNC will try and pursue AGN or others for possibly infringing on some of these patents.

2. Any concern that Botox won't be used as an active comparator arm in P3? I guess the flip side is nice that just have to beat placebo so lower hurdle.

3. Did you finalize your thoughts on what you expect to be the new indication for RT002?